|
|
Post by peppy on Jan 9, 2023 20:52:37 GMT -5
I thought one of the benefits of V-Go was that is was a place to use more the insulin Mannkind has bought or is contracted to buy? MNKD is contracted to buy regular insulin. slower. although if taken with Afrezza, perhaps no need for second dose. |
|
|
|
Post by hellodolly on Jan 10, 2023 7:06:42 GMT -5
I thought one of the benefits of V-Go was that is was a place to use more the insulin Mannkind has bought or is contracted to buy? MNKD is contracted to buy regular insulin. slower. although if taken with Afrezza, perhaps no need for second dose. "Slower" and "Lower" have a nice ring to it when you're talking about combining them. Besides the cute little ring to it, I wonder how they actually perform when used together. |
|
|
|
Post by sayhey24 on Jan 10, 2023 7:34:52 GMT -5
I thought one of the benefits of V-Go was that is was a place to use more the insulin Mannkind has bought or is contracted to buy? V-Go uses your favorite RAA sold by one of MNKD's competitors. The benefit of V-Go is for those T2s on a basal who have now progressed to also needing mealtime insulin. Instead of injecting you manually push the button. Of course if they had been put on afrezza first, like Mike who is now using afrezza, they probably would never have progressed. |
|
|
|
Post by runner on Jan 10, 2023 19:51:40 GMT -5
From the wording of the press release, it seems like MC is presenting in person at the JPM conference. I believe this might be the first in-person presentation by him since Covid began. Anyone know for sure if that's the case?
|
|
|
|
Post by rayskum on Jan 10, 2023 20:38:17 GMT -5
From the wording of the press release, it seems like MC is presenting in person at the JPM conference. I believe this might be the first in-person presentation by him since Covid began. Anyone know for sure if that's the case? He is already at JPM conference. Martine acknowledged him in her presentation. |
|
|
|
Post by akemp3000 on Jan 10, 2023 20:39:45 GMT -5
Martine thanked him for being in the audience during her presentation yesterday. He's scheduled to speak at 11:15 pacific time on Thursday so yes.
|
|
|
|
Post by phdedieu12 on Jan 10, 2023 21:46:54 GMT -5
Yes, he's been there, and will present Thursday
|
|
|
|
Post by hellodolly on Jan 12, 2023 9:44:50 GMT -5
Yes, he's been there, and will present Thursday 2:15 EST |
|
|
|
Post by celo on Jan 12, 2023 10:12:00 GMT -5
Be nice if Mike said something about future quarterly revenue expectations, but probably will not. Have to wait for the quarterlies.
Maybe something about Afrezza sales raising with new medicare designation?
If not much is said, the stock should fall a little. Probably not a lot.
|
|
|
|
Post by akemp3000 on Jan 12, 2023 10:28:40 GMT -5
Be nice if Mike said something about future quarterly revenue expectations, but probably will not. Have to wait for the quarterlies. Maybe something about Afrezza sales raising with new medicare designation? If not much is said, the stock should fall a little. Probably not a lot. Agree. Wall Street doesn't seem to pay a lot of attention to presentations like this and move the pps much one way or the other. Would love to be proven wrong! |
|
|
|
Post by Thundersnow on Jan 12, 2023 14:41:48 GMT -5
DROP THE FUCKING MIC......
Mike hit the ball out of the park!!!
I wish he elaborated on the financials.
|
|
|
|
Post by Clement on Jan 12, 2023 15:00:54 GMT -5
MNKD-101 (clofazimine) projected to start Phase 2/3 about mid-year this year!
|
|
|
|
Post by longliner on Jan 12, 2023 15:01:07 GMT -5
DROP THE FUCKING MIC...... Mike hit the ball out of the park!!! I wish he elaborated on the financials. To elaborate, wheeee longs gonna be rich..... |
|
|
|
Post by cjm18 on Jan 12, 2023 15:05:51 GMT -5
MNKD-101 (clofazimine) projected to start Phase 2/3 about mid-year this year! 2/3? |
|
|
|
Post by Clement on Jan 12, 2023 15:22:47 GMT -5
MNKD-101 (clofazimine) projected to start Phase 2/3 about mid-year this year! 2/3? What is a phase 2/3 trial? From the National Cancer Institute: A study that tests how well a new treatment works for a certain type of cancer or other disease and compares the new treatment with a standard treatment. Phase II/III clinical trials may also provide more information about the safety and side effects of the new treatment. Combining phases II and III may allow research questions to be answered more quickly or with fewer patients. Also called phase 2/phase 3 clinical trial www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-ii-iii-clinical-trial |
|
